ValiRx plc (VAL.L)
- Previous Close
3.4500 - Open
0.0000 - Bid --
- Ask --
- Day's Range
0.0000 - 0.0000 - 52 Week Range
0.0000 - 15.0000 - Volume
432,000 - Avg. Volume
777,955 - Market Cap (intraday)
4.566M - Beta (5Y Monthly) 0.63
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0300 - Earnings Date Jun 3, 2024 - Jun 7, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19. ValiRx plc was incorporated in 2000 and is based in Nuneaton, the United Kingdom.
www.valirx.comRelated News
Performance Overview: VAL.L
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VAL.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VAL.L
Valuation Measures
Market Cap
4.57M
Enterprise Value
3.70M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.09
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-1.51
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-47.22%
Return on Equity (ttm)
-74.39%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-2.41M
Diluted EPS (ttm)
-0.0300
Balance Sheet and Cash Flow
Total Cash (mrq)
891.25k
Total Debt/Equity (mrq)
0.73%
Levered Free Cash Flow (ttm)
-1.85M
Research Analysis: VAL.L
Company Insights: VAL.L
VAL.L does not have Company Insights